Heart failure drug may ease tissue congestion without harming blood flow

NCT ID NCT05152940

Completed Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the diabetes drug ertugliflozin can reduce fluid buildup in the skin and tissues of people with heart failure. 28 adults with reduced heart function took the drug or a placebo for one month each. Researchers measured skin water and sodium content to see if the drug relieves congestion better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ertugliflozin
What this could lead to: If successful, this could show that ertugliflozin relieves tissue congestion in heart failure without affecting blood volume, potentially improving symptoms.
What could go wrong: This is a small, early-phase study with only 28 participants, so results may not apply broadly. The drug may not show a clear benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGESTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGESTION HEART FAILURE WITH REDUCED EJECTION FRACTION

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.